State of Alaska Department of Revenue Has $951,000 Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

State of Alaska Department of Revenue lowered its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 2.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,337 shares of the medical instruments supplier’s stock after selling 262 shares during the period. State of Alaska Department of Revenue owned approximately 0.05% of LeMaitre Vascular worth $951,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Flputnam Investment Management Co. lifted its holdings in shares of LeMaitre Vascular by 3.6% in the 4th quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier’s stock worth $269,000 after purchasing an additional 102 shares in the last quarter. Norden Group LLC raised its holdings in LeMaitre Vascular by 4.5% during the fourth quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier’s stock worth $218,000 after buying an additional 103 shares during the last quarter. Blue Barn Wealth LLC lifted its stake in shares of LeMaitre Vascular by 4.4% in the fourth quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier’s stock valued at $229,000 after buying an additional 104 shares in the last quarter. CBIZ Investment Advisory Services LLC lifted its stake in shares of LeMaitre Vascular by 38.5% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 117 shares in the last quarter. Finally, Sanctuary Advisors LLC grew its holdings in shares of LeMaitre Vascular by 6.0% during the fourth quarter. Sanctuary Advisors LLC now owns 2,065 shares of the medical instruments supplier’s stock valued at $207,000 after buying an additional 117 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Insider Transactions at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 76,868 shares of the stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $85.79, for a total transaction of $6,594,505.72. Following the completion of the transaction, the chief executive officer now directly owns 1,796,783 shares of the company’s stock, valued at $154,146,013.57. This represents a 4.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 100,000 shares of company stock worth $8,556,857 in the last ninety days. Company insiders own 9.50% of the company’s stock.

LeMaitre Vascular Stock Down 2.5%

LeMaitre Vascular stock opened at $82.40 on Friday. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $109.58. The company has a debt-to-equity ratio of 0.48, a quick ratio of 13.83 and a current ratio of 16.49. The firm’s 50-day simple moving average is $83.82 and its 200 day simple moving average is $89.08. The stock has a market cap of $1.86 billion, a PE ratio of 41.62, a price-to-earnings-growth ratio of 2.23 and a beta of 0.83.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.02). The business had revenue of $59.87 million during the quarter, compared to analysts’ expectations of $57.61 million. LeMaitre Vascular had a return on equity of 13.53% and a net margin of 19.96%. LeMaitre Vascular’s quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.44 EPS. Research analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th were given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.97%. The ex-dividend date was Thursday, May 15th. LeMaitre Vascular’s dividend payout ratio is presently 40.40%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on LMAT. Oppenheimer lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Finally, Lake Street Capital raised their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a report on Friday, February 28th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, LeMaitre Vascular presently has a consensus rating of “Hold” and a consensus target price of $97.83.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.